via The Scripps Research Institute
Findings Point to Potential New Use of an Existing Drug
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.
“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of chemistry at TSRI and a senior author of the study, which is reported online in Nature on October 9, 2013.
Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.
A New Approach
An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.
In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.
Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.
“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of chemistry at TSRI and a senior author of the study, which is reported online in Nature on October 9, 2013.
Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.
A New Approach
An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.
In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.
Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.
Go deeper with Bing News on:
Multiple Sclerosis
- Cybil Shepherd Recalls Daughter Clementine’s Multiple Sclerosis Diagnosis as ‘One of the Most Difficult Days of My Life’
Nile Rodgers & Chic had the crowd grooving well into the night at the 29th Annual Race to Erase MS Gala, which returned to the Fairmont Century Plaza hotel in Century City after being held as ...
- Cybill Shepherd Recalls Daughter Clementine’s Multiple Sclerosis Diagnosis as ‘One of the Most Difficult Days of My Life’
Nile Rodgers & Chic had the crowd grooving well into the night at the 29th Annual Race to Erase MS Gala, which returned to the Fairmont Century Plaza hotel in Century City after being held as a ...
- DMTs Lower Multiple Sclerosis Relapse Risk During Reproductive Therapy
In women with multiple sclerosis and clinically isolated syndrome, disease modifying therapy during assisted reproductive technology seems to reduce relapse risk ...
- J&J Subsidiary Sues Pharma Co.s Over Multiple Sclerosis Medication Patents
The lawsuit was brought by Eckert Seamans Cherin & Mellott and Desmarais LLP on behalf of Johnson & Johnson subsidiary Momenta Pharmaceuticals, which asserts two patents related to the injection of ...
- Hundreds support multiple sclerosis with an annual walk in downtown Toledo
Downtown Toledo and the Huntington Center was packed with people eager to 'Walk for MS' and raise awareness for people living with the disease.
Go deeper with Google Headlines on:
Multiple Sclerosis
Go deeper with Bing News on:
MS
- The first Ms. Marvel reactions are in — we've got a new MCU star on our hands
The first reactions to Ms. Marvel, the upcoming Marvel series on Disney Plus, have just hit the internet. Select members of the press have seen the first two episodes of the series, and the good news ...
- Ms. Marvel First Reactions Celebrate And Praise The New MCU Show
The first Ms. Marvel reactions are in, and audiences are praising and celebrating the meaningful Muslim representation in the new MCU show.
- Martin Reunion, College Hill Reboot and Ms. Pat Show Season 2 Among BET+'s Summer Slate — Get Release Dates
BET+ announced its robust summer slate Wednesday, which includes the highly anticipated Martin reunion and new seasons of All the Queen’s Men, Family Business and The Ms. Pat Show. Streaming Thursday, ...
- Early Ms. Marvel Reactions Praise Iman Vellani’s Performance
After watching the first two episodes of Ms. Marvel, most critics have nothing but good things to say about Disney+'s next superhero series.
- MS WFO JACKSON Warnings, Watches, and Advisories
WFO JACKSON Warnings, Watches and Advisories for Wednesday, May 25, 2022 ...